Table 1 Patient characteristics at baseline
From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Number | Percentage | |
|---|---|---|
Eyes/Patients | 80/74 | |
Gender (male) | 45 | 60.8% |
Age (years) | 68.9 ± 9.3 | |
Lens status (phakic) | 69 | 86.3% |
Mean baseline BCVA (letters) | 49.7 ± 18.0 | |
Mean baseline CRT (μm) | 695.1 ± 319.5 | |
PED | 70 | 87.5% |
Subretinal fluids | 71 | 88.8% |
Retinal/subretinal hemorrhage | 25 | 31.3% |